Close Menu

Norton Scientific

According to Matthew Kuruc, COO of PIN member ProFact Proteomics, the network aims to help smaller firms offer complete solutions similar to those increasingly provided by large instrument vendors and to popularize non-mass spec-based proteomics workflows.

Although it's too early to announce biopharma partners, the 13 companies involved in the network are hoping that their collective skills and specialties will attract companies interested in developing drugs targeted to specific proteomic markers in patients.

The group aims to provide solutions for all stages of proteomics research and address "critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring."

The multiplex device, which the company plans to launch next spring, will be pitched as a front end to more expensive, time-consuming protein analysis systems like Wyatt Technologies' line of Dawn instruments, said a company official.

Based in Taiwan, Prisma has made the first sale of Norton's PAM protein monitor in Asia.

Under one deal, AstraNet will sell Norton's protein aggregation monitoring device in Europe, while under another, Advanced Scientific Technologies will sell PAM in the mid-Atlantic region.

New Products: Nov 5, 2010

Premium

Norton Scientific

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.